Portfolio Lab

agilon health, inc.

  • Stock
  • Ticker AGL
  • NYSE

Health care · Health care services · USA

$90.24 +0.83%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of agilon health, inc. since 04/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

AGLGlobal equities (VT)

$10,000 grew to $1,473. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −99.3% in 03/2026, measured from the peak in 06/2021. The old peak has not been reached again yet.

1-year return
+591.0%
5-year return p.a.
−31.4%
Return p.a. since 04/2021
−31.9%
Volatility p.a.
165.1%
Largest decline
−99.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,5221,5331,3951,4351,5691,4201,4951,519
Operating income-108-22-116-131-1944.01224
EBITDA-102-15-109-124-187111931
Net income-10612-104-110-189491835
Earnings per share–0.73-6.31-6.65–2.941.041.97
Balance sheet
Total assets1,7341,9331,7131,5961,2711,5051,5911,566
Liabilities1,2631,4331,3041,2901,1451,3241,3641,285
Equity471500409306127181228281
Cash188137171172174140107174
Long-term debt350.00.00.016151516
Cash flow
Operating cash flow16-32-35-18-2124-5750
Capital expenditure-3.3-3.8-3.3-3.2-3.0-3.1-3.4-3.3
Free cash flow13-36-38-21-2421-6147

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2023 at −22.2%, weakest 2024 at −84.9%. 0 of 4 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$1.97
5 Aug 2026$1.04
6 May 2026$2.94
25 Feb 2026–
4 Nov 2025−$6.65
4 Aug 2025−$6.31
6 May 2025$0.73
25 Feb 2025–
7 Nov 2024–
6 Aug 2024–
7 May 2024–
27 Feb 2024–

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.4bn
Market cap in trading currency
$1.52bn
Enterprise value
$1.37bn
P/E
–
P/S
0.25
P/B
5.40
EV/Sales
0.23
EV/EBITDA
–
Earnings yield
–
FCF yield
-1.1%

Results (last four quarters)

Revenue
$6.00bn
Gross profit
–
EBITDA
−$127m
Net income
−$87.1m
Earnings per share
–
Revenue per share
$357.48
Revenue growth
+5.9%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-2.6%
Net margin
-1.5%
Return on equity
-29.7%
Return on assets
-5.6%

Balance sheet and cash flow

Cash
$174m
Cash per share
$10.38
Financial debt
$30.5m
Debt/equity %
11
Current ratio
1.13
Book value per share
$16.72
Operating cash flow
−$4.23m
Free cash flow
−$17.0m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
16.8m
Volume
266,322
Avg. volume 3 months
217,245
Relative volume
1.2

Price and technicals

Price
$90.24
1 day
+0.8%
52-week high
$129.84
52-week low
$7.91
Distance to 52-week high
−30.5%
Distance to 52-week low
+1,040.8%
Distance to 50-day line
−1.7%
Distance to 200-day line
+26.8%
RSI (14)
41
Volatility 1M
114.0%

Performance

1 week
−22.0%
1 month
−0.1%
3 months
−3.8%
6 months
+4.5%
YTD
+424.1%
1 year
+603.1%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has AGL performed since 04/2021?

$10,000 grew to $1,164 by 20 Nov 2026, which is −31.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is AGL?

Volatility was 165.1% per year, measured on monthly returns. The largest decline from a peak was −99.3%, with the low in 03/2026.

How does AGL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.3% per year at 14.9% volatility, AGL returned −31.9% at 165.1%. The correlation of monthly returns was 0.27; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

agilon health, inc. (AGL): Return and risk | Portfolio Lab